AU642886B2 - T-lymphotropic retrovirus monoclonal antibodies - Google Patents

T-lymphotropic retrovirus monoclonal antibodies Download PDF

Info

Publication number: AU642886B2
Authority: AU; Australia
Prior art keywords: hiv; amino acid; antigen; antibody; epitope
Prior art date: 1989-05-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU58355/90A

Other languages

English (en)

Other versions

AU5835590A (en

Inventor

Bryan T. Butman

Thomas M. Venetta

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Akzo NV

Original Assignee

Akzo NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-05-15

Filing date

1990-05-14

Publication date

1993-11-04

1990-05-14 Application filed by Akzo NV filed Critical Akzo NV

1990-12-18 Publication of AU5835590A publication Critical patent/AU5835590A/en

1993-11-04 Application granted granted Critical

1993-11-04 Publication of AU642886B2 publication Critical patent/AU642886B2/en

2010-05-14 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

241001430294 unidentified retrovirus Species 0.000 title description 8
208000031886 HIV Infections Diseases 0.000 claims description 61
241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 60
239000000427 antigen Substances 0.000 claims description 40
102000036639 antigens Human genes 0.000 claims description 40
108091007433 antigens Proteins 0.000 claims description 40
238000001514 detection method Methods 0.000 claims description 31
125000003275 alpha amino acid group Chemical group 0.000 claims description 27
238000000034 method Methods 0.000 claims description 21
238000009007 Diagnostic Kit Methods 0.000 claims description 14
150000001413 amino acids Chemical class 0.000 claims description 13
230000015572 biosynthetic process Effects 0.000 claims description 13
125000000539 amino acid group Chemical group 0.000 claims description 10
230000008827 biological function Effects 0.000 claims description 9
241000713772 Human immunodeficiency virus 1 Species 0.000 claims 32
230000000052 comparative effect Effects 0.000 claims 3
101710205625 Capsid protein p24 Proteins 0.000 description 24
101710177166 Phosphoprotein Proteins 0.000 description 24
101710149279 Small delta antigen Proteins 0.000 description 24
102100031987 Transmembrane emp24 domain-containing protein 2 Human genes 0.000 description 24
238000002965 ELISA Methods 0.000 description 23
108090000765 processed proteins & peptides Proteins 0.000 description 19
102000004196 processed proteins & peptides Human genes 0.000 description 18
101710072850 Poxin Proteins 0.000 description 17
101710142282 Protein P26 Proteins 0.000 description 17
102100032106 Transmembrane emp24 domain-containing protein 3 Human genes 0.000 description 17
238000003556 assay Methods 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 12
239000000523 sample Substances 0.000 description 12
102000004169 proteins and genes Human genes 0.000 description 9
230000036436 anti-hiv Effects 0.000 description 8
239000006166 lysate Substances 0.000 description 7
239000013641 positive control Substances 0.000 description 7
210000004027 cell Anatomy 0.000 description 6
230000035945 sensitivity Effects 0.000 description 6
208000030507 AIDS Diseases 0.000 description 5
101710177291 Gag polyprotein Proteins 0.000 description 5
101710125418 Major capsid protein Proteins 0.000 description 5
238000003119 immunoblot Methods 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
238000001262 western blot Methods 0.000 description 5
102100023321 Ceruloplasmin Human genes 0.000 description 4
241000725303 Human immunodeficiency virus Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000013642 negative control Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
238000012216 screening Methods 0.000 description 4
108090000565 Capsid Proteins Proteins 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
238000010586 diagram Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000002976 reverse transcriptase assay Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
241000283707 Capra Species 0.000 description 2
102100029905 DNA polymerase epsilon subunit 3 Human genes 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
101710104359 F protein Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108010015780 Viral Core Proteins Proteins 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
208000031504 Asymptomatic Infections Diseases 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
235000021538 Chard Nutrition 0.000 description 1
235000017788 Cydonia oblonga Nutrition 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
108700010908 HIV-1 proteins Proteins 0.000 description 1
101710121996 Hexon protein p72 Proteins 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010087302 Viral Structural Proteins Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
241000894007 species Species 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000010415 tropism Effects 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
AIDS & HIV (AREA)
Hematology (AREA)
Oncology (AREA)
Immunology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AU58355/90A 1989-05-15 1990-05-14 T-lymphotropic retrovirus monoclonal antibodies Ceased AU642886B2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35188289A	1989-05-15	1989-05-15
US351882		1989-05-15

Publications (2)

Publication Number	Publication Date
AU5835590A AU5835590A (en)	1990-12-18
AU642886B2 true AU642886B2 (en)	1993-11-04

Family

ID=23382831

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU58355/90A Ceased AU642886B2 (en)	1989-05-15	1990-05-14	T-lymphotropic retrovirus monoclonal antibodies

Country Status (8)

Country	Link
EP (1)	EP0472659A4 (fr)
JP (1)	JPH04505621A (fr)
KR (1)	KR0168447B1 (fr)
AU (1)	AU642886B2 (fr)
CA (1)	CA2032509A1 (fr)
FI (1)	FI915333A0 (fr)
WO (1)	WO1990014358A1 (fr)
ZA (1)	ZA903492B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK53291D0 (da) *	1991-03-25	1991-03-25	Carlbiotech Ltd As	Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser
SE9101863D0 (sv) *	1991-06-13	1991-06-13	Replico Medical Ab	Peptider, diagnostiskt antigen, vaccinkomposition och foerfarande foer selektering av hiv-stammar
JP4278174B2 (ja) *	1994-10-20	2009-06-10	アンスティテュ・パストゥール	Ｈｉｖ−１のｏグループ（またはサブグループ）レトロウイルス性抗原のヌクレオチド配列
FR2777285B1 (fr) *	1998-04-10	2000-05-19	Bio Merieux	Ligand peptidique presentant une affinite specifique vis-a-vis de la proteine p24 du retrovirus hiv-1
US6818392B2 (en) *	2000-12-06	2004-11-16	Abbott Laboratories	Monoclonal antibodies to human immunodeficiency virus and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3076189A (en) *	1988-02-25	1989-08-31	Bio-Rad Laboratories, Inc.	Novel compositions and methods of use thereof
AU5578590A (en) *	1989-05-22	1990-11-22	Akzo N.V.	Diagnostic test for detecting antibodies directed against antigens of one or more related viruses
AU8976691A (en) *	1990-12-14	1992-06-18	Chiron Behring Gmbh & Co.	Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4755457A (en) *	1985-02-05	1988-07-05	Robert Guroff Marjorie	Method for detecting HTLV-III neutralizing antibodies in sera
US4843011A (en) *	1985-08-01	1989-06-27	Akzo N.V.	Monoclonal antibodies for binding HTLV-III proteins, and cell lines for their production
US4888290A (en) *	1987-11-06	1989-12-19	Coulter Corporation	Monoclonal antibody specific to HIV antigens
US5173399A (en) *	1988-06-10	1992-12-22	Abbott Laboratories	Mouse monoclonal antibodies to hiv-1p24 and their use in diagnostic tests

1990
- 1990-05-08 ZA ZA903492A patent/ZA903492B/xx unknown
- 1990-05-14 JP JP2508986A patent/JPH04505621A/ja active Pending
- 1990-05-14 CA CA002032509A patent/CA2032509A1/fr not_active Abandoned
- 1990-05-14 WO PCT/US1990/002874 patent/WO1990014358A1/fr not_active Application Discontinuation
- 1990-05-14 KR KR1019910700048A patent/KR0168447B1/ko not_active IP Right Cessation
- 1990-05-14 EP EP19900909217 patent/EP0472659A4/en not_active Ceased
- 1990-05-14 AU AU58355/90A patent/AU642886B2/en not_active Ceased
1991
- 1991-11-12 FI FI915333A patent/FI915333A0/fi unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3076189A (en) *	1988-02-25	1989-08-31	Bio-Rad Laboratories, Inc.	Novel compositions and methods of use thereof
AU5578590A (en) *	1989-05-22	1990-11-22	Akzo N.V.	Diagnostic test for detecting antibodies directed against antigens of one or more related viruses
AU8976691A (en) *	1990-12-14	1992-06-18	Chiron Behring Gmbh & Co.	Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof

Also Published As

Publication number	Publication date
EP0472659A4 (en)	1992-04-08
EP0472659A1 (fr)	1992-03-04
ZA903492B (en)	1991-02-27
KR920701243A (ko)	1992-08-11
AU5835590A (en)	1990-12-18
FI915333A0 (fi)	1991-11-12
CA2032509A1 (fr)	1990-11-16
KR0168447B1 (ko)	1999-01-15
WO1990014358A1 (fr)	1990-11-29
JPH04505621A (ja)	1992-10-01

Publication	Publication Date	Title
Palker et al.	1989	Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Moore et al.	1994	Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies
Moore et al.	1995	A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B
Papsidero et al.	1989	Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping
AU625970B2 (en)	1992-07-23	Hiv-3 retrovirus and its use
Kayman et al.	1994	Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains
JP2958346B2 (ja)	1999-10-06	抗ＨＩＶ―２モノクローナル抗体およびそれを用いた抗ＨＩＶ―２ｇｐ４１抗体の検出方法
IE61241B1 (en)	1994-10-19	Monoclonal antibody specific to hiv antigens
US5256561A (en)	1993-10-26	Monoclonal antibody to HIV-2 and uses thereof
WO1990006510A1 (fr)	1990-06-14	Anticorps monoclonaux contre le lentivirus lymphotropique t
US5210181A (en)	1993-05-11	T-lymphotropic retrovirus peptide
Hinkula et al.	1990	Epitope mapping of the HIV-1 gag region with monoclonal antibodies
US5254457A (en)	1993-10-19	Monoclonal antibodies and method for identifying different aids-related viruses
Avrameas et al.	1992	Localisation of three epitopes of the env protein of feline immunodeficiency virus
AU642886B2 (en)	1993-11-04	T-lymphotropic retrovirus monoclonal antibodies
Boucher et al.	1990	Immune response and epitope mapping of a candidate HIV‐1 p17 vaccine HGP30
VanCott et al.	1994	Serotyping international HIV-1 isolates by V3 peptides and whole gp160 proteins using BIAcore
Walther et al.	1995	Evaluation of HIV-1/HIV-2 immunoblots for detection of HIV-2 antibodies
San Hou et al.	2001	Monoclonal antibodies against different epitopes of nonstructural protein ςNS of avian reovirus S1133
Sibille et al.	1995	Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats
Lombardi et al.	1993	Detection of B epitopes on the p24 gag protein of feline immunodeficiency virus by monoclonal antibodies
Rimmelzwaan et al.	1994	Gag-and env-specific serum antibodies in cats after natural and experimental infection with feline immunodeficiency virus
Norrby et al.	1989	Immunochemistry of the dominating antigenic region Ala582 to Cys604 in the transmembranous protein of simian and human immunodeficiency virus.
US5624795A (en)	1997-04-29	Isolation and characterization of a novel chimpanzee lentivirus, designated simian immunodeficiency virus isolate cpz-ant
Chiang et al.	2005	Characterization of a monoclonal antibody specific to the Gag protein of porcine endogenous retrovirus and its application in detecting the virus infection